A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
Battle in a rare form of epilepsy queued up following positive phase III trial.
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
Teva's annus horribilis continues but overall the picture is bright.